Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
June 6, 2023
Assignees:
Ecole Polytechnique Federale de Lausanne (EPFL), Anokion SA
Inventors:
Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
May 23, 2023
Assignees:
Ecole Polytechnique Federale de Lausanne (EPFL), Anokion, SA
Inventors:
Jeffrey A. Hubbell, David Scott Wilson, Stephane Kontos, Kristen Marie Lorentz, Shuning Gai
Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
February 22, 2022
Assignees:
The University of Chicago, Anokion SA
Inventors:
Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
Abstract: The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.
Type:
Application
Filed:
May 9, 2019
Publication date:
August 12, 2021
Applicants:
The University of Chicago, Anokion SA
Inventors:
Jeffrey A. HUBBELL, David Scott WILSON, Kym BRÜNGGEL, Kristen Marie LORENTZ
Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
Type:
Grant
Filed:
February 20, 2015
Date of Patent:
November 3, 2020
Assignees:
ANOKION SA, ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (“EPFL”)
Inventors:
Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
© 2025 Justia
